Reprogramming of the errα and erα target gene landscape triggers tamoxifen resistance in breast cancer

Cancer Research

Volumn 75, Issue 4, 2015, Pages 720-731

  Thewes, Verena ^a   Simon, Ronald ^b   Schroeter, Petra ^a   Schlotter, Magdalena ^a   Anzeneder, Tobias ^c   Büttner, Reinhard ^d   Benes, Vladimir ^e   Sauter, Guido ^b   Burwinkel, Barbara ^f   Nicholson, Robert I ^g   Sinn, Hans Peter ^h   Schneeweiss, Andreas ^h   Deuschle, Ulrich ⁱ   Zapatka, Marc ^a   Heck, Stefanie ^a   Lichter, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ PHENEX PHARMACEUTICALS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RELATED RECEPTOR ALPHA; MESSENGER RNA; PROTEIN P53; TAMOXIFEN; ERRALPHA ESTROGEN-RELATED RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN; FULVESTRANT; NCOA3 PROTEIN, HUMAN; STEROID RECEPTOR COACTIVATOR 3;

AIB1 GENE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG SENSITIVITY; ERALPHA GENE; ERRALPHA GENE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPROGRAMMING; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF 7 CELL LINE; MOLECULAR GENETICS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR RECEPTOR COACTIVATOR 3; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84923206053     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0652     Document Type: Article

References (50)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists' collaborative group. Lancet 1998;351: 1451-67.
2. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007;72:7-25.
3. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004;64:1522-33.
4. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
5. Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, et al. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res 2004;64:4670-6.
6. Heck S, Rom J, Thewes V, Becker N, Blume B, Sinn HP, et al. Estrogenrelated receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma. Cancer Res 2009; 69:5186-93.
7. Chisamore MJ, Wilkinson HA, Flores O, Chen JD. Estrogen-related recep-tor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts. Mol Cancer Ther 2009;8:672-81.
8. Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, Giguere V. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Cancer Res 2010;70: 10277-87.
9. Giguere V, Yang N, Segui P, Evans RM. Identification of a new class of steroid hormone receptors. Nature 1988;331:91-4.
10. Horard B, Vanacker JM. Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endocrinol 2003;31:349-57.
11. Coward P, Lee D, Hull MV, Lehmann JM. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma. Proc Natl Acad Sci U S A 2001;98:8880-4.
12. Lanvin O, Bianco S, Kersual N, Chalbos D, Vanacker JM. Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790. J Biol Chem 2007;282:28328-34.
13. Stein RA, McDonnell DP. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr Relat Cancer 2006;13:S25-32.
14. Lu D, Kiriyama Y, Lee KY, Giguere V. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res 2001;61:6755-61.
15. Deblois G, Hall JA, Perry MC, Laganiere J, Ghahremani M, Park M, et al. Genome-wide identification of direct target genes implicates estrogenrelated receptor alpha as a determinant of breast cancer heterogeneity. Cancer Res 2009;69:6149-57.
16. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res 2007;5:71-85.
17. Gojis O, Rudraraju B, Gudi M, Hogben K, Sousha S, Coombes RC, et al. The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol 2010;7:83-9.
18. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, et al. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 2009;28:1418-28.
19. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011;43:27-33.
20. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012;481:389-93.
21. Waldmann A, Anzeneder T, Katalinic A. Patients andmethods of the PATH biobank - a resource for breast cancer research. Geburtshilfe und Frauenheilkunde 2014;74:361-69.
22. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006;118:2190-4.
23. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008;14: 1744-52.
24. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifenresistant MCF-7 cells. Endocrinology 2003;144:1032-44.
25. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001;142: 2776-88.
26. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 2013;19:901-8.
27. Stone A, Valdes-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, et al. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PloS ONE 2012;7:e40466.
28. Welboren WJ, Sweep FC, Span PN, Stunnenberg HG. Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer 2009;16:1073-89.
29. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-54.
30. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006;118:1699-712.
31. Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW. Estrogen receptor alpha is themajor driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat 2013;139:71-80.
32. Beelen K, Zwart W, Linn SC. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 2012;9: 529-41.
33. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early crossresistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997; 57:3486-93.
34. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alpha and estro-gen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62: 6510-8.
35. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
36. Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 2011;18:565-77.
37. Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, et al. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006;10:487-99.
38. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapyresistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013;4:1116-30.
39. Toy W, Shen Y,WonH, Green B, Sakr RA, WillM, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
40. Weiner M, Skoog L, Fornander T, Nordenskjold B, Sgroi DC, Stal O. Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer. Ann Oncol 2013;24:1994-9.
41. Burandt E, Jens G, Holst F, Janicke F, Muller V, Quaas A, et al. Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. Breast Cancer Res Treat 2013;137:745-53.
42. Stein RA, Chang CY, Kazmin DA, Way J, Schroeder T, Wergin M, et al. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res 2008;68:8805-12.
43. Barry JB, Giguere V. Epidermal growth factor-induced signaling in breast cancer cells results in selective target gene activation by orphan nuclear receptor estrogen-related receptor alpha. Cancer Res 2005;65:6120-9.
44. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006;20:3120-32.
45. Vanacker JM, Bonnelye E, Chopin-Delannoy S, Delmarre C, Cavailles V, Laudet V. Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha). Mol Endocrinol 1999;13:764-73.
46. Kallen J, Schlaeppi JM, Bitsch F, Filipuzzi I, Schilb A, Riou V, et al. Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome prolif-erator-activated receptor coactivator-1alpha. J Biol Chem 2004;279: 49330-7.
47. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011;62:233-47.
48. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 2012;6:289-97.
49. Allred DC, Brown P, Medina D. The origins of estrogen receptor alphapositive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004;6:240-5.
50. Luo J, Sladek R, Carrier J, Bader JA, Richard D, Giguere V. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor alpha. Mol Cell Biol 2003;23:7947-56.